Ongoing Clinical Trials

Title A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir.
Description The study will assess the efficacy and safety of maribavir treatment in transplant recipients with cytomegalovirus (CMV) infections that are resistant or refractory to prior anti-CMV treatment.
Title Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients.
Description The study will evaluate the efficacy and safety of MK-8228 in Adult Kidney transplant recipients for prevention of cytomegalovirus (CMV)  disease in kidney transplant recipients
Title A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Optional Oral Fluconazole Step‑down in the Treatment of Subjects with Candidemia and/or Invasive Candidiasis.
Description The study is assessing the safety, tolerability and efficacy of Reafungin in the treatment of subjects with Candidemai and/or Invasive Candidiasis compared with standard of care treatments such as Caspofungin and fluconazole.
Title A Comparative Study to Evaluate Dual Amplification PCR Testing (MYCODART-PCR) of 6 Candida species in Patients with Documented Candidemia/Invasive Candidiasis. FUNGAL INFECTION NEW DIAGNOSTICS (FIND) STUDY.
Description The objective of this study is to compare the sensitivity and specificity of the MYCODART-PCR Candida Panel vs blood cultures in the detection of 6 different Candida species in blood specimens from patients with documented candidemia and/or invasive candidiasis.
Title A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of Ridinilazole (200 mg, bid) for 10 days with Vancomycin (125 mg, QID) for 10 Days in the Treatment of Clostridium difficile Infection (CDI).
Description The study will compare the safety and tolerability of 10 days dosing of ridinilazole with vancomycin in the treatment of patient with CDI.
Title Clinical Evaluation of the QuantiFERON CMV Assay
Description The study will validate the use of the QuantiFERON CMV Assay in the clinical setting for reassessing the risks of CMV infection in D+/R- Solid Organ Transplant (SOT) recipients after the completion of antiviral prophylaxis.
Title A multicenter, open-label, sponsor-blinded, randomized, active-controlled, parallel group, pivotal study to evaluate the efficacy, safety, and tolerability of murepavadin given with ertapenem versus an anti-pseudomonal-ß-lactam-based antibiotic in adult subjects with nosocomial pneumonia suspected or confirmed to be due to Pseudomonas aeruginosa.
Description The study is assessing the safety, tolerability and efficacy of murepavadin in adult subjects with nosocomial pneumonia suspected or confirmed to be due to Pseudomonas aeruginosa and compare length of intensive care unit (ICU) and hospital days with those subjects treated with standard of care (SOC) medications.
Title A Phase 2B, Open-label, Single-arm, First in Human Study of F901318 (orotomide)  as Treatment of Invasive Fungal Infections Due to Lomentospora prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options (FORMULA-OLS).
Description The study is assessing the safety, tolerability and efficacy of orotomide in the treatment of invasive fungal infections and other resistant fungi in patients who lack alternative treatments.
Title SERES-012: ECOSPOR III: A Phase 3 Multicenter, RandomizeEd, Double Blind, -Placebo COntrolled, -Parallel Group- Study to Evaluate the Safety, Tolerability, and Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium difficile Infection (CDI) in Adults Who Have Received Antibacterial Drug Treatment for Recurrent CDI.
Description The study is assessing the safety, tolerability and efficacy of SER-109 vs placebo to reduce recurrence of C. difficile Infection (CDI) in adults who have received antibacterial drug treatment.
Title ECOSPOR IV: An Open-Label Phase 3 Extension of Study Series-012 Evaluating SER-109 in Adult Subjects with Recurrent Clostridium difficle Infection (RCDI)
Description The study will validate the use of the QuantiFERON CMV Assay in the clinical setting for reassessing the risks of CMV infection in D+/R- Solid Organ Transplant (SOT) recipients after the completion of antiviral prophylaxis.
Division of Infectious Diseases
Academic Administrative Office

818 Scaife Hall
3550 Terrace Street
Pittsburgh, PA 15261
412-383-7963

Center for Care of Infectious Diseases

Falk Medical Building
3601 Fifth Avenue
Pittsburgh, PA 15213
Patient Appointments: 412-647-7228